Bivalent booster effectiveness against severe COVID-19

outcomes in Finland, September 2022 – January 2023

3 Eero Poukka^{1,2}, Sirkka Goebeler³, Hanna Nohynek¹, Tuija Leino¹, Ulrike Baum¹

- 6 1. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute
- 7 for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
- 8 2. Department of Public Health, Faculty of Medicine, University of Helsinki, Yliopistonkatu 4, 00100
- 9 Helsinki, Finland

1

2

4

5

- 10 3. Forensic Medicine Unit, Department of Government services, Finnish Institute for Health and
- 11 Welfare, Mannerheimintie 166, 00300 Helsinki, Finland

Abstract

Bivalent COVID-19 vaccines were introduced in 2022 but knowledge of how their effectiveness against severe COVID-19 outcomes is sustained over time is currently limited. In Finnish register-based cohort analyses, we compared the risk of severe COVID-19 outcomes among those who received bivalent vaccination (exposed) between 1 September 2022 and 31 January 2023 to those who did not (unexposed). Among elderly aged 65–120 years, bivalent vaccination reduced the risk of hospitalisation and death due to COVID-19. Among the elderly the hazard ratios comparing exposed and unexposed ranged from 0.36 to 0.43 during the first 14–30 days since bivalent vaccination but signs of waning were observed as soon as two months after vaccination. Among the chronically ill aged 18–64 years bivalent vaccination did not reduce the risk of severe COVID-19 outcomes. These results are crucial for further developing COVID-19 vaccination programme worldwide.

Main text

Due to the emergence of new SARS-CoV-2 variants with immune evasive capabilities¹, new, bivalent COVID-19 vaccines, containing mRNA that encodes the spike proteins of the original virus strain and the Omicron variant, were developed in 2022. The European Medicines Agency authorized the first (BA.1 and BA.4-5) bivalent vaccines in September 2022^{2,3}, which were promptly recommended in Finland as a booster for all people aged 65 years or more and those aged 18–64 years with underlying medical conditions predisposing to severe COVID-19.

In previous studies, bivalent vaccines have increased the protection against severe outcomes^{4–9}. However, the duration of this protection is currently unclear. Thus, studies estimating the effectiveness of bivalent vaccines over time are needed as policy makers are considering recommendation of a second bivalent booster. Presently, policies vary between countries: some countries decided to recommend a second

bivalent booster¹⁰, while others do not yet recommend further boosters for spring 2023.

The aim of this study was to estimate the effectiveness of BA.1 and BA.4-5 bivalent COVID-19 vaccines against severe COVID-19 outcomes one, two and three months after vaccination in Finland based on national register data. Since bivalent boosters were primarily offered to individuals who had received at least two monovalent doses, our study was restricted to these vaccinees. To control for confounding, all analyses were adjusted for a set of potential confounders; a negative control outcome was used to assess the presence of residual confounding.

Results

36

37

38

39

40

41

42

43

The study cohorts included 1,197,700 elderly aged 65–120 years and 444,683 chronically-ill individuals aged 44 45 18-64 years (Supplementary Table S3). Only a small proportion of each cohort had been laboratory-46 confirmed SARS-CoV-2-positive prior to the study (Supplementary Table S4). The 2022-2023 influenza 47 vaccination coverage reached 58% in the elderly cohort and 37% in the chronically ill cohort. 48 During the study 627,378 (52%) elderly and 66,871 (15%) chronically ill were vaccinated with a bivalent 49 booster; approximately a third of them received Comirnaty BA.1 while the other two thirds received 50 Comirnaty BA.4-5. Spikevax bivalent vaccines were used only in small quantities. The median time since 51 bivalent vaccination by the end of follow-up was 75 days (interguartile range 61-85 days) and 73 days 52 (interquartile range 54–88 days) among the elderly and chronically ill, respectively. 53 Among the elderly, we observed 1,721 hospitalisations due to COVID-19, 1,002 deaths due to COVID-19 54 and 809 deaths in which COVID-19 was a contributing factor. During the first 14-30 and 31-60 days since vaccination, a bivalent booster lowered the risk of hospitalisation due to COVID-19 (hazard ratio [HR] 0.43, 55 56 95% confidence interval [CI] 0.33-0.57; HR 0.43, 95% CI 0.33-0.57), death due to COVID-19 (0.39, 0.26-57 0.57; 0.57, 0.42-0.77) and death in which COVID-19 was a contributing factor (0.36, 0.24-0.54; 0.41, 0.29-58 0.57) (Fig. 1, Supplementary Table S5). Thereafter, the HRs increased: during the third month, i.e. 61–90 59 days since vaccination, the HR estimates for the aforementioned outcomes were 0.74 (95% CI 0.50-1.09), 60 0.74 (0.49-1.13) and 0.42 (0.25-0.69). When stratified by age, the HRs for 65-79-year-olds and 80-120-

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

year-olds were similar (Fig. 2, Supplementary Table S6). Both BA.1 and BA.4-5 bivalent vaccines reduced the risk of severe COVID-19 outcomes and the HRs were similar (Supplementary Table S7). Among the chronically ill we observed 240 hospitalisations due to COVID-19, 16 deaths due to COVID-19 and 18 deaths in which COVID-19 was a contributing factor. HR of hospitalisation due to COVID-19 was estimated at 0.82 (95% CI 0.32-2.07) for days 14-30 since bivalent vaccination and 1.57 (0.78-2.07) for the subsequent 30 days. The HR for the other two outcomes could not be estimated (Supplementary Table S8). In our negative control outcome analysis, we observed 9,447 emergency room visits due to injury among the elderly and 2,173 such visits among the chronically ill. We found no difference in the risk of injury among elderly who received a bivalent booster and those who did not (Supplementary Table S5). However, among the chronically ill the risk of injury appeared slightly elevated (Supplementary Table S8). Figure 1. Hazard ratios among the elderly. Covariate-adjusted hazard ratios (with 95% confidence intervals) comparing the hazards of severe COVID-19 outcomes in 65-to-120-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine, Finland, September 2022-January 2023. Figure 2. Age-stratified hazard ratios among the elderly. Covariate-adjusted hazard ratios (with 95% confidence intervals) comparing the hazards of severe COVID-19 outcomes in 65-to-120-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine stratified by age group, Finland, September 2022-January 2023.

Discussion

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

In our Finnish study, bivalent boosters reduced the risk of severe COVID-19 outcomes among the elderly. By contrast, among the chronically-ill 18-64-year-olds the risk was similar among those who received bivalent vaccine and those who did not. Among the elderly a bivalent booster provided highest protection during the first two months after vaccination, but thereafter signs of waning were observed. The effectiveness among individuals aged 65-79 years and those aged 80 years or more was similar. Previously, the effectiveness of bivalent vaccines against severe COVID-19 outcomes has been studied in the USA, Israel, the United Kingdom, Italy and in the Nordic countries 4-9,11,12. Compared to our analyses, a similar Israeli study⁸ conducted among people aged 65 years or more reported slightly higher BA.4-5 bivalent booster effectiveness against severe COVID-19 outcomes. In an English analysis including individuals aged 50 years or more, the BA.1 bivalent booster effectiveness against hospitalisation due to COVID-19 was similar to our results, but no waning was observed after ten weeks since bivalent vaccination⁷. This English study is currently the only study, apart from ours, estimating the bivalent booster effectiveness against severe COVID-19 outcomes over time. Therefore, further studies assessing the existence and rate of waning will be needed to decide 1) whether annual boosters should be recommended for vulnerable groups and 2) whether the development of new COVID-19 vaccines inducing longer-lasting immune responses should be pursued. Among the chronically ill we did not observe bivalent vaccination to reduce the risk of severe COVID-19 outcomes, although previous studies have found a benefit among working-age adults^{6,12}. This may be due to several reasons. Firstly, only a small proportion of the cohort received a bivalent booster, and the negative control outcome analysis indicated the presence of residual confounding. Secondly, individuals who did not receive the booster might have had higher likelihood of unregistered SARS-CoV-2 infection and thus hybrid immunity prior to the study, which could have led to underestimation of the effectiveness. Thirdly, the number of cases among the chronically ill was small, which together with the low bivalent vaccine uptake led to unprecise estimates for that group. Fourthly, a good baseline protection due to

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

monovalent vaccinations and hybrid immunity among the chronically ill might have limited the additional benefit of a bivalent booster. As another limitation, we observed a decreased risk of severe COVID-19 outcomes during the first 0-13 days since bivalent vaccination. This was probably caused by selection (i.e. healthy vaccinee) bias as individuals with acute respiratory symptoms, a predeterminant of severe COVID-19 outcomes, were not advised to seek vaccination. However, it should be noted that the effect of this bias diminishes over time and is likely negligible after 13 or latest 30 days since vaccination. Our study has also several strengths. The study was timely and representative. We used the monovalent vaccinated as the reference group, whose characteristics are probably more like the characteristics of the bivalent vaccinated compared to those of the unvaccinated. Furthermore, we did not observe meaningful residual confounding in the negative control outcome analysis among the elderly. The recording of vaccinations and COVID-19 outcomes is mandatory, and the utilised registers have been well maintained as they have been used for routine surveillance of the COVID-19 vaccination programme and the COVID-19 pandemic in Finland. In conclusion, bivalent boosters reduced the risk of hospitalisation and death due to COVID-19 among the elderly but not among chronically-ill, working-age adults. Because we found signs of waning already after 60 days since bivalent vaccination additional boosters for the elderly could be an option at some time point in the future. However, the need for further boosting should also be considered in the light of the epidemic situation and economic analyses. Authors' contributions. EP, UB, HN and TL conceptualised the study. UB conducted the statistical analysis and SG provided the death certificate data. EP and HN reviewed the literature. EP and UB drafted the manuscript. EP, UB, SG HN and TL gave comments and revised the manuscript.

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Conflict of interests. HN is a member of Finnish National Immunization Technical Advisory Groups and chairman of Strategic Advisory Group of Experts on Immunization for World Health Organization. Funding. EP received a grant from The Finnish Medical Foundation. No other sources of external funding. Research ethics. By Finnish law, the Finnish Institute for Health and Welfare (THL) is the national expert institution to carry out surveillance on the impact of vaccinations in Finland (Communicable Diseases Act, https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf). Neither specific ethical approval of this study nor informed consent from the participants was needed. Data availability. By Finnish law, the authors are not permitted to share individual-level register data. The computing code is available upon request. Acknowledgements. We thank Erika Lindh and Aapo Juutinen for providing Supplementary Figure 1 as well as Heini Salo and Toni Lehtonen for the register-based identification of individuals with medical conditions predisposing to severe COVID-19. Additional thanks go to all the colleagues at the Finnish Institute for Health and Welfare (THL) who curate the register data. Lastly, we are grateful for our fruitful collaboration with Statistics Finland. References 1. Qu, P. et al. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med 387, 1329-1331 (2022). 2. EMA. First adapted COVID-19 booster vaccines recommended for approval in the EU. European Medicines Agency https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccinesrecommended-approval-eu (2022). 3. EMA. Adapted vaccine targeting BA.4 and BA.5 Omicron variants original SARS-CoV-2 recommended for approval. European Medicines Agency https://www.ema.europa.eu/en/news/adapted-vaccinetargeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval (2022).

- 4. Andersson, N. W. et al. Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster
- 153 *vaccines in the Nordic countries.* http://medrxiv.org/lookup/doi/10.1101/2023.01.19.23284764 (2023)
- 154 doi:10.1101/2023.01.19.23284764.
- 155 5. Tenforde, M. W. et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–
- 156 Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among
- 157 Immunocompetent Adults VISION Network, Nine States, September–November 2022. MMWR Morb.
- 158 *Mortal. Wkly. Rep.* **71**, 1616–1624 (2022).
- 159 6. Surie, D. et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–
- Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years IVY Network, 18 States,
- 161 September 8–November 30, 2022. MMWR Morb. Mortal. Wkly. Rep. **71**, 1625–1630 (2022).
- 162 7. Public Health England. COVID-19 vaccine surveillance report: week 5. (2023).
- 8. Arbel, R. et al. Effectiveness of the Bivalent mRNA Vaccine in Preventing Severe COVID-19 Outcomes: An
- Observational Cohort Study. SSRN Journal (2022) doi:10.2139/ssrn.4314067.
- 9. Fabiani, M. et al. Protection against severe COVID-19 after second booster dose of adapted bivalent
- (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12
- September to 11 December 2022. Eurosurveillance 28, (2023).
- 168 10. Folkhälsomyndigheten. Fortsatt vaccination mot covid-19 under 2023 för personer 65 år och äldre samt
- för yngre med riskfaktorer Folkhälsomyndigheten. https://www.folkhalsomyndigheten.se/nyheter-
- 170 och-press/nyhetsarkiv/2022/december/fortsatt-vaccination-mot-covid-19-under-2023-for-personer-65-
- ar-och-aldre-samt-for-yngre-med-riskfaktorer/ (2022).
- 172 11. Lin, D.-Y. et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl J Med
- 173 NEJMc2215471 (2023) doi:10.1056/NEJMc2215471.
- 174 12. Tadmor, T., Melamed, G., Alapi, H., Patalone, T. & Rokach, L. The Effectiveness of Bivalent mRNA
- 175 Omicron Containing Booster Vaccines Among Patients with Hematological Neoplasms.
- 176 https://www.ssrn.com/abstract=4343759 (2023) doi:10.2139/ssrn.4343759.

13. Baum, U. *et al.* Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation
 among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study. *PLoS ONE* 16, e0258704 (2021).

180

Online Methods

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

We conducted population-based cohort analyses linking national register data from Finland using a unique person identifier. The study period was from 1 September 2022 to 31 January 2023, when Omicron BA.5 and its sublineages were the dominant SARS-CoV-2 strains (Supplementary Figure S1). In analogy to our previous study¹³, we formed two cohorts of individuals aged 65-120 years (the elderly) and individuals aged 18-64 years with comorbidities or medical therapies predisposing to severe COVID-19 (the chronically ill, Supplementary Tables S1-2). We included only individuals that had received at least two monovalent COVID-19 vaccine doses (Comirnaty/ tozinameran/ BNT162b2, Spikevax/ elasomeran/ mRNA-1273, or Vaxzevria/ ChAdOx1-SARS-COV-2/ AZD1222). In addition, we excluded individuals that were hospitalised due to COVID-19 at the beginning of the study or had received a COVID-19 vaccination with too short dosing interval or a bivalent vaccination prior to the study (Supplementary Table S3). The exposure was defined as vaccination with a BA.1 or BA.4-5 bivalent vaccine recorded in the Finnish Vaccination Register and was time-dependently categorized into seven groups: not vaccinated with a bivalent booster (the reference), and 0-13, 14-30, 31-60, 61-90, 91-120 and 121 or more days since vaccination with a bivalent booster. The bivalent vaccines included in this study were either based on Comirnaty or Spikevax as other bivalent vaccines were not available in Finland during the study period. The severe COVID-19 outcomes were hospitalisation due to COVID-19, death due to COVID-19 and death in which COVID-19 was a contributing factor. Hospitalisations, recorded in the Care Register for Health Care, had to fulfil the following two criteria to be considered as hospitalisations due to COVID-19: 1) The primary diagnosis was COVID-19 (International Classification of Diseases, 10th revision: U07.1, U07.2), acute respiratory tract infection (J00- J22, J46) or severe complication of lower respiratory tract infections (J80-84, J85.1, J86). 2) A positive PCR- or antigen SARS-CoV-2 sample was taken from the hospitalized patient in the period extending from 14 days before to 7 days after hospital admission and registered in the National Infectious Diseases Register.

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

To define the two COVID-19 death outcomes, we used data collected from death certificates. In Finland, physicians record the cause of death of their patients as well as other significant conditions contributing to death in death certificates that are thereafter reviewed by medico-legal specialists at the Finnish Institute for Health and Welfare prior to forming statistics. In our study, death due to COVID-19 included all deaths in which COVID-19 was recorded as the cause of death in the death certificate. The cases in which COVID-19 was a contributing factor to death were equally retrieved from the death certificates. For the study, the data from reviewed death certificates were computerized into a database by medico-legal specialists accepting the ICD10 codes U07.1, U07.2, U09, and U10 as COVID-19 diagnosis. In addition, we defined a fourth endpoint, which we assumed to be unaffected by the exposure. This negative control outcome was any emergency room visit due to injury (International Classification of Diseases, 10th revision: S00-T14) recorded in the Care Register for Health Care. We considered nine covariates as confounders in our study: age group, region of residency, sex (Population Information System), hospitalisation between 1 September 2021 and 31 August 2022 (Care Register for Health Care), presence of comorbidities or medical therapies predisposing to severe COVID-19 (Care Register for Health Care, Register of Primary Health Care visits, Special Reimbursement Register for Medicine Expenses and Prescription Centre database, residency in a long-term care facility (Care Register for Social Care), seasonal influenza vaccination in 2022–2023, number of monovalent COVID-19 vaccinations (Finnish Vaccination Register) and last laboratory-confirmed SARS-CoV-2 infection prior to the study (National Infectious Diseases Register). SARS-CoV-2 infections were categorised into pre-Omicron infections (before 2022) and Omicron infections (since 2022). The individual follow-up period started earliest on 1 September 2022 and latest 91 days after the last monovalent COVID-19 vaccination or laboratory-confirmed SARS-CoV-2 infection prior to the study. Each individual was followed until death, outcome of interest, day 14 (if the outcome of interest was hospitalisation due to COVID-19) or day 60 after laboratory-confirmed SARS-CoV-2 infection, a second bivalent vaccination, a monovalent vaccination and 31 January 2023, whichever occurred first.

Separately for each cohort, we compared the hazard of the three severe COVID-19 outcomes between unexposed and exposed individuals taking into account time since bivalent vaccination. The hazard ratio (HR) was estimated using Cox regression with time in the study as the underlying time scale and adjusted for the aforementioned covariates. Additionally, we stratified the elderly cohort by age differentiating between individuals aged 65–79 years and those aged 80 years or more and analysed the HR separately for BA.1 and BA.4-5 bivalent vaccines. For these analyses, we combined the second and third and the fourth and fifth time since vaccination interval to account for the expectably small number of cases in these exposure groups.

To evaluate the presence of residual confounding, we estimated the hazard ratio for the negative control outcome and expected to find no difference between the unexposed and exposed. The analysis was conducted as described above considering the negative control outcome as the outcome of interest. However, individuals with residence in Helsinki-Uusimaa had to be excluded due to data collection problems affecting the identification of emergency room visits based on register data in the region. All analyses were performed in R 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

- Hospitalisation due to COVID-19
- △ Death due to COVID-19
- ▼ Death in which COVID-19 was a contributing factor





